Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
US10519130B2 · kind B2 · utility
8Cited by
69References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 2, 2018 |
| Grant date | Dec 31, 2019 |
| Priority date | — |
| Expiry date | Nov 2, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R4′, X1, Y1, Y2, Y3, Y4, n, and m are described herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.